about us

our story FUNDING & GRANTS OUR SCIENTIFIC CO-FOUNDERS OUR MANAGEMENT OUR BOARD

science

F prau. in Iflammatory Bowel Diseases F prau. in Cancer MANUFACTURING LIVE BIOThERAPEUTICS

pipeline

Overview Patients Exl01 in Crohn's diseases
Exl01 in Cancer Immunotherapy

newsroom

about us

about us

Our story funding & grants Our Scientific Co-founders Our mission Our values

Our management Our board

science

science

Exl01 Crohn's Disease Faecalibacterium Prausnitzii in Inflammatory Bowel Diseases Faecalibacterium Prausnitzii immuno-oncology Faecalibacterium Prausnitzii in Recurrent Clostridium difficile Infections Tryptophan metabolism Manufacturing Live Biotherapeutics

pipeline

pipeline

EXL01’s description & clinical trials Patients EXL01 in Crohn’s Disease EXL01 in Cancer Immunotherapy EXL01 in Immuno-Oncology EXL01 in recurrent Clostridium difficile infections EXL02 EXL03 Regulatory Expertise Intellectual Property

newsroom

newsroom

Corporate Presentation Publications News Upcoming Events

about us

our board

contact

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

EXELIOM BIOSCIENCES
ALL RIGHTS RESERVED.

about us

OUR STORY OUR PARTNERS Our Scientific Co-founders OUR MANAGEMENT OUR BOARD

exl01

F.prau IN I.B.D.F.prau IN immuno-oncology MANUFACTURING LIVE BIOTHERAPEUTICS

partnerships

Overview Patients EXL01 IN CROHN’S DISEASE EXL01 IN Cancer immunotherapy REGULATORY EXPERTISE INTELLECTUAL PROPERTY

newsroom

Corporate presentation Publications News News Upcoming Events

Created by BlackMotion